122 results
To investigate the influence of short implants (6 mm in length) on marginal peri-implant bone levels, clinical variables and patient satisfaction.
Serum hepcidin levels are elevated in hemodialysis patients and may contribute to functional iron impairment and thus to ESA-resistance. Kinetics of hepcidin in hemodialysis patients has not been studied in detail. This study is designed to provide…
To investigate the influence of platform-switched implant-abutment connections (smaller diameter abutment on wider diameter implant) of short implants (8.5 mm in length) on marginal peri-implant bone levels and clinical variables.
The primary objective of this study is to investigate the improvement of masticatory function of implant-supported RPD treatment in free-ending, bilateral mandibular partial edentulism. The secondary objectives include patient satisfaction (OHIP14…
The aim of this study to evaluate the clinical performance of short implants (4 mm in length) in the resorbed posterior mandibular region of partially edentulous patients that will be restored with a single crown.
To investigate the influence of different implant neck designs on marginal peri-implant bone levels and clinical variables.
Primary research question: Is there a difference in plasma- and dialysate clearances of middle molecules and larger molecules, with different electrical charges, between treatment with standard haemodialysis, high-flux haemodialysis and on-line…
The objective of this study is to test the safety, tolerability and anti-tumor activity of the combination of the investigational products epacadostat and pembrolizumab, compared to pembrolizumab as mono therapy, in patients with advanced/…
Primary Objectives:(1) Objective: To compare the overall survival (OS) in subjects with R/M HNSCC treated with pembrolizumab compared to standard treatment.Secondary Objectives:PD-L1 Positive Population:(1) Objective: To compare Overall Survival (OS…
Primary objectives:(1) To determine the safety and tolerability of pembrolizumab. (2) To evaluate the Overall Response Rate (ORR) of pembrolizumab by independent central review according to the International Working Group (IWG) response criteria (…
The objective of this study is to test the safety, tolerability and anti-tumor activity of the combination of the investigational products epacadostat and pembrolizumab, compared to pembrolizumab as mono therapy, in patients with cisplatin-…
Primary Objectives(1) To evaluate the overall survival (OS) of subjects with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy (recurrent/progressive metastatic…
Objectives: To compare PFS using RECIST 1.1 as assessed by BICR and OS in PD-L1 positive subjects and all subjects between the following treatment comparisons:(a) Pembrolizumab + chemotherapy versus chemotherapy(b) Pembrolizumab versus…
1. To evaluate the progression-free-survival (PFS) in patients with ipilimumab refractory advanced MEL receiving either MK-3475 or chemotherapy.2. To evaluate the overall survival (OS) in patients with ipilimumab refractory advanced MEL receiving…
1. To evaluate progression-free-survival (PFS) in patients with advanced MEL receiving either Pembrolizumab or IPI.2. To evaluate overall survival (OS) in patients with advanced MEL receiving either Pembrolizumab or IPI.
Primary objectives: To explore the safety, feasibility, and the immune-activating capacity of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapySecondary…
1) Objective: To compare the overall survival (OS) of previously-treated subjects with NSCLC in the strongly positive PD-L1 stratum treated with MK-3475 compared to docetaxel.2) Objective: To compare progression-free survival (PFS) per RECIST 1.1 by…
Objective- To evaluate anti-tumor activity of pembrolizumab (MK-3475) by evaluating the absence of high risk NMIBC or progressive disease in subjects with CIS at baseline (cohort A) and subjects without CIS at baseline (cohort B).Hypotheses:-…
The objective of this study is to test the safety, tolerability and anti-tumor activity of the combination of the investigational products epacadostat and pembrolizumab, compared to pembrolizumab as mono therapy, in patients with unresectable or…
Primary objective To evaluate the Overall Response Rate (CR/PRrate) in patients treated with pembrolizumab for recurrent or progressive PCNSL after MTX-based first-line therapy To evaluate the safety of pembrolizumab in subjects diagnosed with…